Highlights
1 patent
About
Minimally Invasive Solution for Type 2 Diabetes and Obesity
Endobetix is developing a minimally invasive, nonsurgical implant that mimics the hormonal benefits offered by bariatric surgery. Implanted endoscopically, the Endobetix Bile Diversion Device (BDD) reroutes bile and pancreatic secretions from the duodenum to the lower part of the small intestine. This diversion changes the hormonal balance and induces the release of key hormones such as GLP-1 to improve glucose tolerance and reduce fat absorption. The BDD can be implanted by gastroenterologists and bariatric surgeons in an outpatient procedure.
Identity
| Name | Endobetix |
|---|---|
| Slug | endobetix |
| Type / kind | startup |
| Crunchbase ID | endobetix |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6k-68LDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Dec 2016 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ address | 17 Tchelet St. Misgav, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProviders
Business models
B2B
Tags
medical-devicesminimally-invasivegastroenterologyobesitynon-surgicaldiabetesendoscopyhospitalsdoctors
Funding
| Total raised | $650K |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}